Search

Savara Inc

Закрыт

СекторЗдравоохранение

4.82 10.55

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.74

Макс.

4.88

Ключевые показатели

By Trading Economics

Доход

-2.9M

-40M

Прибыль на акцию

-0.16

Сотрудники

70

EBITDA

-2.9M

-40M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+134.64% upside

Дивиденды

By Acuity

Следующий отчет о доходах

10 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-202M

972M

Предыдущая цена открытия

-5.73

Предыдущая цена закрытия

4.82

Savara Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 нояб. 2026 г., 21:02 UTC

Savara Inc. shares are advancing, showing a significant increase since Thursday's close, with unusually high trading volume despite earlier pulling back from a session high.

5 нояб. 2026 г., 21:04 UTC

Correlated Moves

Savara Inc. shares fell sharply, reflecting a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF also experienced significant losses.

4 нояб. 2026 г., 20:52 UTC

Savara Inc. shares fell sharply, remaining below their 20-day moving average amid unusually high market volume and significant fluctuations earlier in the session.

3 нояб. 2026 г., 21:07 UTC

Savara Inc. shares are advancing, building on Monday's close, despite pulling back from an earlier session high amid overall modest market gains.

2 нояб. 2026 г., 23:06 UTC

Savara Inc. shares advanced in after-market trading, gaining ground since Monday's close, following three consecutive sessions that finished lower.

30 окт. 2026 г., 20:08 UTC

Savara Inc. shares fell significantly, reflecting broader market weakness, and finished notably lower compared to Thursday's close.

29 окт. 2026 г., 20:06 UTC

Savara Inc. shares fell sharply as the broader market closed lower after an early peak.

28 окт. 2026 г., 20:02 UTC

Savara Inc. shares are advancing, diverging from a broader market downturn observed during Wednesday's session.

27 окт. 2026 г., 21:01 UTC

Savara Inc. shares declined modestly in after-market trading, remaining near the bottom of their range after a notable drop earlier in the session.

26 окт. 2026 г., 23:56 UTC

Savara Inc's shares advanced in after-market trading, reflecting a notable rise since Monday's close, though still below its 20-day moving average.

23 окт. 2026 г., 21:02 UTC

Savara Inc shares advanced in after-market trading, reaching a high shortly after the market closed before settling to a more modest gain.

22 окт. 2026 г., 20:07 UTC

News

Savara Inc's stock is declining after the company reiterated its Market Outperform rating and $10 price target, following new Molbreevi data presented at the CHEST conference.

21 окт. 2026 г., 23:16 UTC

Savara Inc is trading higher in after-market hours, gaining since Wednesday's close.

20 окт. 2026 г., 23:06 UTC

Savara Inc. shares advanced modestly in after-market hours, following a session that saw earlier peak gains before settling lower.

19 окт. 2026 г., 22:51 UTC

Savara Inc shares are moving higher in after-market trading, supported by an upward trend in the broader market, despite earlier session pullbacks.

16 окт. 2026 г., 22:26 UTC

Savara Inc shares traded lower in after-market hours, reflecting ongoing weakness amid broader market concerns over rising U.S. import and export prices.

15 окт. 2026 г., 23:06 UTC

Savara Inc's shares are advancing in after-market trading, gaining ground since Thursday's close, with a cumulative return peaking at just under 1.9%.

14 окт. 2026 г., 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

13 окт. 2026 г., 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 окт. 2026 г., 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 окт. 2026 г., 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 окт. 2026 г., 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 окт. 2026 г., 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 окт. 2026 г., 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2 окт. 2026 г., 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1 окт. 2026 г., 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

30 сент. 2026 г., 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

28 сент. 2026 г., 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

25 сент. 2026 г., 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

24 сент. 2026 г., 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Savara Inc Прогноз

Целевая цена

By TipRanks

134.64% рост

Прогноз на 12 месяцев

Средняя 11.333 USD  134.64%

Максимум 16 USD

Минимум 9 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Savara Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat